Products
Efungumab Biosimilar scFv Antibody Fragment (HSP90 Homolog) for Research
Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-167-1mg | 1mg | 3090 |
| GMP-Bios-ab-167-10mg | 10mg | |
| GMP-Bios-ab-167-100mg | 100mg | |
| GMP-Bios-ab-167-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody |
| INN Name | Efungumab |
| Target | Heat Shock Protein 90 Homolog |
| Format | scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | NeuTec Pharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Breast cancer;Candidiasis |
| Development Tech | na |
